超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Genta
Genta（Nasdaq 上市代碼 GNTA 一家專門開發抗癌藥物的生物科技公司）－ 1998年Genta這個的由大眾投資的上市公司宣布失敗，并且當時市值只有500萬美元。在這種情況下Oyler先生被邀請擔任這個公司的CEO。 在擔任CEO后Oyler先生為公司爭取到了新的資金，重新啟動了7個臨床的項目并聘請了全新的管理團隊。由于Oyler先生的出色工作，Genta的業績穩步提高，逐漸走出了低谷。 目前Genta的市值為16億美元。


Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform : DNA/RNA-based Medicines and Small Molecules. Genasense? (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta has completed enrollment to the AGENDA Trial , a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite? (gallium nitrate injection) , which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. Genta is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite? and Genasense? are available on a ”named-patient“ basis in countries outside the United States.

Genta is committed to improving the lives of patients by providing innovative solutions in the treatment of cancer. Our team of scientists, physicians and business people have extensive experience in the identification, development and commercialization of oncology products.

?